Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
0 hedge funds and large institutions have $0 invested in Neon Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 43 closing their positions.
52.4% less ownership
Funds ownership: 52.4% → 0% (-52%)
100% less funds holding
Funds holding: 43 → 0 (-43)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $39.9M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 43
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV GP III
Boston,
Massachusetts
|
-$25.7M |
| 2 |
Armistice Capital
New York
|
-$2.77M |
| 3 |
BlackRock
New York
|
-$2.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.9M |
| 5 |
Athanor Capital
New York
|
-$1.45M |
NTGN Hedge Fund Activity: Q2 2020 in Review
0 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q2 2020, worth a combined $0 — down 100% from $39.9M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of NTGN and 0 opened new positions — a net loss of 43 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was TRV GP III, exiting entirely with an estimated $25.7M sold.
- 0 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q2 2020, down from 43 in Q1 2020.
- Funds reported $0 of Neon Therapeutics, Inc. Common Stock stock for Q2 2020, down 100% quarter-over-quarter.
- 0 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q2 2020 and 43 closed out, a net change of -43 holders.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q2 2020 was TRV GP III, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2020.